MedTrace Logo

Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma

NCT03138031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-05-14

No results posted yet for this study

Summary

Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.

Conditions

  • Hepatocellular Carcinoma Non-resectable

Interventions

PROCEDURE

Percutaneous ethanol alcohol injection

Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of "8" limits the procedure. Post-procedure analgesia may be required.

Sponsors & Collaborators

  • The National Ribat University

    lead OTHER

Principal Investigators

  • Osama M Elsanousi, MD · The National Ribat University

  • Murtada M Mohamed, MD · Ribat University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2018-05-01
Completion
2018-05-30

Countries

  • Sudan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138031 on ClinicalTrials.gov